GlyCardial Diagnostics has completed patient recruitment in EDICA trial: a multicenter international clinical study for the early detection of Myocardial Ischaemia.
February 11, 202111 February, 2021
Our vision is to improve the early diagnosis
of cardiac ischemic events to reduce
the impact of the disease on patients' life
Our vision is to improve the early diagnosis
of cardiac ischemic events to reduce
the impact of the disease on patients' life
of cardiac ischemic events to reduce
the impact of the disease on patients' life
GlyCardial Diagnostics is developing Apo J-Glyc as a novel biomarker for the diagnosis and prognosis of myocardial ischemia
Why?
Cardiovascular diseases (CVD) are the leading cause of death globally (30% total deaths). Each year more than 17.5M people die from CVD and it is expected to reach up to 23.6M by 2030. Specifically, ischemic heart disease (IHD) is the leading cause of death from CVD accounting for more 10 million deaths each year worldwide.
What?
Early detection of ischemia (lack of blood supply) is essential to prevent irreversible myocardial damage. Nowadays, there is an unmet medical need for early diagnosis of ischemia and the prediction of patients’ evolution after an ischemic event.
Apo J-Glyc is a novel biomarker for the diagnosis and prognosis of myocardial ischemia.
When?
By the end of 2021 we expect to have validated the first laboratory-based in vitro diagnostic test for the quantification of blood levels of Apo J-Glyc as a novel biomarker of cardiac ischemia.
